Formulation: A solid
Formal Name: N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-carbamic acid, methyl ester
Purity: ≥98%
Formula Markup: C19H16F2N8O2
Formula Weight: 426,4
Shelf life (days): 1460
CAS Number: 1350653-20-1
Notes: Vericiguat is a stimulator of soluble guanylyl cyclase (sGC).{62821} It stimulates the formation of cGMP in CHO cells expressing recombinant rat sGC in the absence and presence of the nitric oxide (NO) donor SNAP (Item No. 82250; EC50s = 1,005 and 39 nM, respectively), an effect that can be reversed by the sGC inhibitor ODQ (Item No. 81410). Vericiguat inhibits phenylephrine-induced contractions in isolated rabbit saphenous artery rings, rabbit aortic rings, and canine femoral vein rings (IC50s = 798, 692, and 3,072 nM, respectively), as well as decreases the coronary perfusion pressure in isolated perfused rat hearts in a concentration-dependent manner. It decreases proteinuria and increases survival in rats expressing mouse renin ((mRenR2)27), a transgenic model for hypertension, when administered at doses of 3 or 10 mg/kg. Formulations containing vericiguat have been used in the treatment of heart failure.
English
Deutsch
